Journal Article
. 2018 Mar; 115(15):3912-3917.
doi: 10.1073/pnas.1801524115.

Anti-CTLA-4 therapy requires an Fc domain for efficacy

Jessica R Ingram 1 Olga S Blomberg 2 Mohammad Rashidian 2 Lestat Ali 1 Scott Garforth 3 Elena Fedorov 3 Alexander A Fedorov 3 Jeffrey B Bonanno 3 Camille Le Gall 2 Stephanie Crowley 1 Camilo Espinosa 1 Tamara Biary 4 Edmund J Keliher 5 Ralph Weissleder 5 Steven C Almo 3 Stephanie K Dougan 1 Hidde L Ploegh 6 Michael Dougan 7 
Affiliations
  • PMID: 29581255
  •     46 References
  •     57 citations

Abstract

Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved "checkpoint"-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate antibody-dependent cellular phagocytosis, but the contribution of simple CTLA-4 blockade remains unknown. To understand the role of CTLA-4 blockade in the complete absence of Fc-dependent functions, we developed H11, a high-affinity alpaca heavy chain-only antibody fragment (VHH) against CTLA-4. The VHH H11 lacks an Fc portion, binds monovalently to CTLA-4, and inhibits interactions between CTLA-4 and its ligand by occluding the ligand-binding motif on CTLA-4 as shown crystallographically. We used H11 to visualize CTLA-4 expression in vivo using whole-animal immuno-PET, finding that surface-accessible CTLA-4 is largely confined to the tumor microenvironment. Despite this, H11-mediated CTLA-4 blockade has minimal effects on antitumor responses. Installation of the murine IgG2a constant region on H11 dramatically enhances its antitumor response. Coadministration of the monovalent H11 VHH blocks the efficacy of a full-sized therapeutic antibody. We were thus able to demonstrate that CTLA-4-binding antibodies require an Fc domain for antitumor effect.

Keywords: CTLA-4; cancer; checkpoint blockade; immunotherapy; single-domain antibody.

3V: cavity, channel and cleft volume calculator and extractor.
Neil R Voss, Mark Gerstein.
Nucleic Acids Res, 2010 May 19; 38(Web Server issue). PMID: 20478824    Free PMC article.
Highly Cited.
64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.
Kei Higashikawa, Katsuharu Yagi, +4 authors, Shuichi Enomoto.
PLoS One, 2014 Nov 05; 9(11). PMID: 25365349    Free PMC article.
Nanobodies: natural single-domain antibodies.
Serge Muyldermans.
Annu Rev Biochem, 2013 Mar 19; 82. PMID: 23495938
Highly Cited. Review.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.
P S Linsley, J Bradshaw, +3 authors, R S Mittler.
Immunity, 1996 Jun 01; 4(6). PMID: 8673700
Highly Cited.
Localized CD47 blockade enhances immunotherapy for murine melanoma.
Jessica R Ingram, Olga S Blomberg, +8 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2017 Sep 07; 114(38). PMID: 28874561    Free PMC article.
Nanobodies as tools for in vivo imaging of specific immune cell types.
Kurt De Groeve, Nick Deschacht, +6 authors, Geert Raes.
J Nucl Med, 2010 Apr 17; 51(5). PMID: 20395332
Structure of murine CTLA-4 and its role in modulating T cell responsiveness.
D A Ostrov, W Shi, +2 authors, S G Nathenson.
Science, 2000 Oct 29; 290(5492). PMID: 11052947
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
PD-L1 is an activation-independent marker of brown adipocytes.
Jessica R Ingram, Michael Dougan, +12 authors, Hidde L Ploegh.
Nat Commun, 2017 Sep 25; 8(1). PMID: 28935898    Free PMC article.
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
Alison M Paterson, Scott B Lovitch, +9 authors, Arlene H Sharpe.
J Exp Med, 2015 Sep 16; 212(10). PMID: 26371185    Free PMC article.
Highly Cited.
The future of immune checkpoint therapy.
Padmanee Sharma, James P Allison.
Science, 2015 Apr 04; 348(6230). PMID: 25838373
Highly Cited. Review.
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
Sean P Arlauckas, Christopher S Garris, +9 authors, Mikael J Pittet.
Sci Transl Med, 2017 May 12; 9(389). PMID: 28490665    Free PMC article.
Highly Cited.
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.
Masahisa Jinushi, Yukoh Nakazaki, +3 authors, Glenn Dranoff.
J Clin Invest, 2007 Jun 09; 117(7). PMID: 17557120    Free PMC article.
Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Jonathan T Sockolosky, Michael Dougan, +5 authors, K Christopher Garcia.
Proc Natl Acad Sci U S A, 2016 Apr 20; 113(19). PMID: 27091975    Free PMC article.
Highly Cited.
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, +8 authors, James P Allison.
Cell, 2017 Aug 15; 170(6). PMID: 28803728    Free PMC article.
Highly Cited.
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
G Dranoff, E Jaffee, +7 authors, R C Mulligan.
Proc Natl Acad Sci U S A, 1993 Apr 15; 90(8). PMID: 8097319    Free PMC article.
Highly Cited.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.
Mohammad Rashidian, Jessica R Ingram, +11 authors, Hidde L Ploegh.
J Exp Med, 2017 Jul 02; 214(8). PMID: 28666979    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Immune therapy for cancer.
Michael Dougan, Glenn Dranoff.
Annu Rev Immunol, 2008 Nov 15; 27. PMID: 19007331
Highly Cited. Review.
Coinhibitory Pathways in Immunotherapy for Cancer.
Susanne H Baumeister, Gordon J Freeman, Glenn Dranoff, Arlene H Sharpe.
Annu Rev Immunol, 2016 Mar 02; 34. PMID: 26927206
Highly Cited. Review.
Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4.
Sebastian Zeissig, Britt-Sabina Petersen, +11 authors, Richard S Blumberg.
Gut, 2014 Nov 05; 64(12). PMID: 25367873    Free PMC article.
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Desirée Schubert, Claudia Bode, +37 authors, Bodo Grimbacher.
Nat Med, 2014 Oct 21; 20(12). PMID: 25329329    Free PMC article.
Highly Cited.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E A Tivol, F Borriello, +3 authors, A H Sharpe.
Immunity, 1995 Nov 01; 3(5). PMID: 7584144
Highly Cited.
Noninvasive imaging of immune responses.
Mohammad Rashidian, Edmund J Keliher, +8 authors, Hidde L Ploegh.
Proc Natl Acad Sci U S A, 2015 Apr 23; 112(19). PMID: 25902531    Free PMC article.
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
IAP inhibitors enhance co-stimulation to promote tumor immunity.
Michael Dougan, Stephanie Dougan, +11 authors, Glenn Dranoff.
J Exp Med, 2010 Sep 15; 207(10). PMID: 20837698    Free PMC article.
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
David J DiLillo, Jeffrey V Ravetch.
Cell, 2015 May 16; 161(5). PMID: 25976835    Free PMC article.
Highly Cited.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
The B7 family revisited.
Rebecca J Greenwald, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2005 Mar 18; 23. PMID: 15771580
Highly Cited. Review.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Frederick Arce Vargas, Andrew J S Furness, +29 authors, Sergio A Quezada.
Immunity, 2017 Apr 16; 46(4). PMID: 28410988    Free PMC article.
Highly Cited.
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Hye Sun Kuehn, Weiming Ouyang, +33 authors, Gulbu Uzel.
Science, 2014 Sep 13; 345(6204). PMID: 25213377    Free PMC article.
Highly Cited.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
The B7-CD28 superfamily.
Arlene H Sharpe, Gordon J Freeman.
Nat Rev Immunol, 2002 Mar 26; 2(2). PMID: 11910893
Highly Cited. Review.
Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber.
Science, 2015 Apr 04; 348(6230). PMID: 25838375
Highly Cited. Review.
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Rodrigo Vazquez-Lombardi, Claudia Loetsch, +8 authors, Daniel Christ.
Nat Commun, 2017 May 13; 8. PMID: 28497796    Free PMC article.
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Michael Dougan.
Front Immunol, 2017 Dec 13; 8. PMID: 29230210    Free PMC article.
Highly Cited. Review.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
The use of 18F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer.
Mohammad Rashidian, Edmund Keliher, +9 authors, Hidde Ploegh.
ACS Cent Sci, 2016 Mar 10; 1(3). PMID: 26955657    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.
Bryan C Barnhart, Michael Quigley.
Immunol Cell Biol, 2016 Dec 16; 95(4). PMID: 27974746
Review.
Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs).
David R Maass, Jorge Sepulveda, Anton Pernthaner, Charles B Shoemaker.
J Immunol Methods, 2007 Jun 15; 324(1-2). PMID: 17568607    Free PMC article.
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Jeremy D Waight, Dhan Chand, +14 authors, Nicholas S Wilson.
Cancer Cell, 2018 Jun 13; 33(6). PMID: 29894690    Free PMC article.
Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Peter Bannas, Friedrich Koch-Nolte.
Front Immunol, 2018 Nov 22; 9. PMID: 30459772    Free PMC article.
Review.
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Kerstin Schütze, Katharina Petry, +10 authors, Friedrich Koch-Nolte.
Front Immunol, 2018 Dec 14; 9. PMID: 30524421    Free PMC article.
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.
Quentin Lecocq, Katty Zeven, +7 authors, Nick Devoogdt.
Biomolecules, 2019 Oct 02; 9(10). PMID: 31569553    Free PMC article.
CTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers.
Charles Brown, Farzad Sekhavati, +4 authors, Keith E Steele.
J Histochem Cytochem, 2019 Oct 15; 67(12). PMID: 31609157    Free PMC article.
NK Cell-Fc Receptors Advance Tumor Immunotherapy.
Emilio Sanseviero.
J Clin Med, 2019 Oct 17; 8(10). PMID: 31614774    Free PMC article.
Review.
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment.
Christina M Paluskievicz, Xuefang Cao, +3 authors, Jonathan S Bromberg.
Front Immunol, 2019 Nov 05; 10. PMID: 31681327    Free PMC article.
Review.
Theranostics in immuno-oncology using nanobody derivatives.
Quentin Lecocq, Yannick De Vlaeminck, +6 authors, Karine Breckpot.
Theranostics, 2019 Nov 07; 9(25). PMID: 31695800    Free PMC article.
Review.
Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer.
Peter Wierstra, Gerwin Sandker, +5 authors, Sandra Heskamp.
EJNMMI Radiopharm Chem, 2019 Nov 07; 4(1). PMID: 31696402    Free PMC article.
Review.
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Emilio Sanseviero, Erin M O'Brien, +16 authors, Erica L Stone.
Cancer Immunol Res, 2019 Jun 27; 7(8). PMID: 31239316    Free PMC article.
Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin.
Patrizia Murer, Jonathan D Kiefer, +4 authors, Dario Neri.
J Invest Dermatol, 2018 Dec 14; 139(6). PMID: 30543899    Free PMC article.
A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope.
Dong Li, Jing Li, Huanyu Chu, Zhuozhi Wang.
MAbs, 2020 Feb 15; 12(1). PMID: 32054416    Free PMC article.
The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
Quentin Deveuve, Laurie Lajoie, Benjamin Barrault, Gilles Thibault.
Front Immunol, 2020 Mar 03; 11. PMID: 32117299    Free PMC article.
Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Luisa Barrueto, Francheska Caminero, +3 authors, Rahul R Deshmukh.
Transl Oncol, 2020 Mar 03; 13(3). PMID: 32114384    Free PMC article.
Review.
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
Anping Li, Ming Yi, +3 authors, Kongming Wu.
J Hematol Oncol, 2019 Apr 03; 12(1). PMID: 30935414    Free PMC article.
Highly Cited. Review.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota.
Arthur E Frankel, Sachin Deshmukh, +8 authors, Andrew Y Koh.
Integr Cancer Ther, 2019 Apr 25; 18. PMID: 31014119    Free PMC article.
Review.
Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Huijuan Song, Pengxiang Yang, +3 authors, Weiwei Wang.
Theranostics, 2019 Jun 01; 9(8). PMID: 31149045    Free PMC article.
Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors.
Hanwen Wang, Richard J Sové, +6 authors, Aleksander S Popel.
Front Bioeng Biotechnol, 2020 Mar 12; 8. PMID: 32158754    Free PMC article.
Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH.
Stephanie J Crowley, Patrick T Bruck, +10 authors, Stephanie K Dougan.
Open Biol, 2020 Feb 06; 10(2). PMID: 32019478    Free PMC article.
Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Michael Dougan.
Curr Gastroenterol Rep, 2020 Mar 19; 22(4). PMID: 32185493
Review.
IgG and Fcγ Receptors in Intestinal Immunity and Inflammation.
Tomas Castro-Dopico, Menna R Clatworthy.
Front Immunol, 2019 Apr 30; 10. PMID: 31031776    Free PMC article.
Review.
T cell costimulation, checkpoint inhibitors and anti-tumor therapy.
Dipankar Nandi, Sanmoy Pathak, +6 authors, Vijayamahantesh.
J Biosci, 2020 Apr 30; 45. PMID: 32345776
Review.
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses.
Qiuxia Qu, Zhiwei Zhai, +3 authors, Binfeng Lu.
Front Immunol, 2020 May 01; 11. PMID: 32351508    Free PMC article.
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Marisa O Peluso, Ammar Adam, +10 authors, Alison M Paterson.
J Immunother Cancer, 2020 Apr 30; 8(1). PMID: 32345627    Free PMC article.
ImmunoPET: Concept, Design, and Applications.
Weijun Wei, Zachary T Rosenkrans, +3 authors, Weibo Cai.
Chem Rev, 2020 Mar 24; 120(8). PMID: 32202104    Free PMC article.
Review.
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.
Chunxiao Li, Ping Jiang, +2 authors, Junjie Wang.
Mol Cancer, 2020 Jul 19; 19(1). PMID: 32680511    Free PMC article.
Review.
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review).
Wararat Chiangjong, Somchai Chutipongtanate, Suradej Hongeng.
Int J Oncol, 2020 Jul 25; 57(3). PMID: 32705178    Free PMC article.
Review.
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics.
Emily Y Yang, Khalid Shah.
Front Oncol, 2020 Aug 15; 10. PMID: 32793488    Free PMC article.
Review.
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.
Lukas Amon, Lukas Hatscher, +2 authors, Christian H K Lehmann.
Pharmaceutics, 2020 Jul 18; 12(7). PMID: 32674488    Free PMC article.
Review.
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Shin Foong Ngiow, Arabella Young.
Front Immunol, 2020 Aug 28; 11. PMID: 32849557    Free PMC article.
Review.
Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.
Emily B Ehlerding, Hye Jin Lee, +6 authors, Weibo Cai.
Am J Cancer Res, 2019 Feb 14; 9(1). PMID: 30755811    Free PMC article.
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy.
Esteban Cruz, Veysel Kayser.
Biologics, 2019 May 24; 13. PMID: 31118560    Free PMC article.
Highly Cited. Review.
Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer.
Timothée Chanier, Patrick Chames.
Antibodies (Basel), 2019 Sep 24; 8(1). PMID: 31544819    Free PMC article.
Review.
Development and characterization of CD54-targeted immunoPET imaging in solid tumors.
Weijun Wei, Dawei Jiang, +5 authors, Weibo Cai.
Eur J Nucl Med Mol Imaging, 2020 Apr 13; 47(12). PMID: 32279097    Free PMC article.
Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
Jin-Hwan Han, Mingmei Cai, +9 authors, Sybil M Genther Williams.
Front Immunol, 2020 Oct 30; 11. PMID: 33117369    Free PMC article.
Overcoming Immune Evasion in Melanoma.
Kevinn Eddy, Suzie Chen.
Int J Mol Sci, 2020 Dec 02; 21(23). PMID: 33256089    Free PMC article.
Review.
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs.
Ainhoa Moliner-Morro, Daniel J Sheward, +4 authors, Leo Hanke.
Biomolecules, 2020 Dec 17; 10(12). PMID: 33322557    Free PMC article.
Nanobodies as Versatile Tool for Multiscale Imaging Modalities.
Marco Erreni, Tilo Schorn, Francesca D'Autilia, Andrea Doni.
Biomolecules, 2020 Dec 24; 10(12). PMID: 33353213    Free PMC article.
Review.
Noninvasive Imaging of Cancer Immunotherapy.
Omar Abousaway, Taha Rakhshandehroo, +2 authors, Mohammad Rashidian.
Nanotheranostics, 2021 Jan 05; 5(1). PMID: 33391977    Free PMC article.
Review.
Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer.
Asimina Koulouridi, Ippokratis Messaritakis, +2 authors, John Souglakos.
Cancers (Basel), 2020 Dec 31; 13(1). PMID: 33375686    Free PMC article.
Review.
mRNA in cancer immunotherapy: beyond a source of antigen.
Lien Van Hoecke, Rein Verbeke, +4 authors, Sandra Van Lint.
Mol Cancer, 2021 Mar 05; 20(1). PMID: 33658037    Free PMC article.
Review.
The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation.
Jakub Rosik, Bartosz Szostak, Filip Machaj, Andrzej Pawlik.
Int J Mol Sci, 2021 Apr 04; 22(6). PMID: 33802937    Free PMC article.
Review.
ImmunoPET Imaging of TIM-3 in Murine Melanoma Models.
Weijun Wei, Dawei Jiang, +4 authors, Weibo Cai.
Adv Ther (Weinh), 2021 Apr 24; 3(7). PMID: 33889713    Free PMC article.
Mechanisms of Action of the PGLYRP1/Tag7 Protein in Innate and Acquired Immunity.
D V Yashin, L P Sashchenko, G P Georgiev.
Acta Naturae, 2021 May 08; 13(1). PMID: 33959389    Free PMC article.
Nanobodies for Medical Imaging: About Ready for Prime Time?
Léa Berland, Lauren Kim, +5 authors, Mohammad Rashidian.
Biomolecules, 2021 May 01; 11(5). PMID: 33925941    Free PMC article.
Review.
Nanobodies in cancer.
Elisha R Verhaar, Andrew W Woodham, Hidde L Ploegh.
Semin Immunol, 2020 Dec 05; 52. PMID: 33272897    Free PMC article.
Review.
Nanobodies as in vivo, non-invasive, imaging agents.
Thibault J Harmand, Ashraful Islam, Novalia Pishesha, Hidde L Ploegh.
RSC Chem Biol, 2021 Jul 03; 2(3). PMID: 34212147    Free PMC article.
Review.
Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.
Alicia Teijeira Crespo, Stephanie Burnell, +7 authors, Alan L Parker.
Immunology, 2021 Feb 28; 163(4). PMID: 33638871    Free PMC article.
Review.
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.
Yingyue Liu, Xiangxiang Zhou, Xin Wang.
J Hematol Oncol, 2021 Aug 19; 14(1). PMID: 34404434    Free PMC article.
Review.
Radiolabeling Strategies of Nanobodies for Imaging Applications.
Jim Küppers, Stefan Kürpig, +2 authors, Susanne Lütje.
Diagnostics (Basel), 2021 Sep 29; 11(9). PMID: 34573872    Free PMC article.
Review.
Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients.
Jonathan Marable, Damien Ruiz, +8 authors, Maninder Sandey.
Sci Rep, 2021 Oct 23; 11(1). PMID: 34675296    Free PMC article.
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges.
Hao-Tian Liu, Meng-Jie Jiang, +5 authors, Jian-Hong Zhong.
Front Oncol, 2021 Nov 09; 11. PMID: 34745958    Free PMC article.
Review.
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Monika Semmrich, Jean-Baptiste Marchand, +15 authors, Björn Frendéus.
J Immunother Cancer, 2022 Jan 22; 10(1). PMID: 35058324    Free PMC article.
Immune checkpoint blockade in HIV.
Celine Gubser, Chris Chiu, Sharon R Lewin, Thomas A Rasmussen.
EBioMedicine, 2022 Feb 06; 76. PMID: 35123267    Free PMC article.
Review.
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
Yosuke Sato, Cierra N Casson, +14 authors, Michael H Shaw.
Cancer Immunol Immunother, 2022 Mar 04;. PMID: 35237846
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy.
Megan M Y Hong, Saman Maleki Vareki.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326731    Free PMC article.
Review.